Dr Isabel Cunningham discusses some of the important studies presented at the 2016 ASH meeting.
Daratumumab plus lenalidomide and dexamethasone (DRd) is superior to lenalidomide plus dexamethasone (Rd).
Idarubicin plus high-dose cytarabine (HDAC) with or without vorinostat was not superior to 7+3 chemotherapy.
Daratumumab plus bortezomib and dexamethasone (DVd) is superior to bortezomib plus dexamethasone (Vd).
Some patients with chronic myeloid leukemia (CML) who have maintained deep molecular responses for at least 2 years can safely discontinue nilotinib.
There were no differences in molecular relapse-free survival between patients with prior 4.5 log reduction but detectable disease and those with undetectable disease
Tyrosine kinase inhibitor (TKI) cessation appears feasible and safe in patients with chronic myeloid leukemia in chronic phase (CML-CP).
Tyrosine kinase inhibitors (TKIs) can be safely and successfully discontinued a second time despite failing first discontinuation.
Generic formulations of imatinib appear to be non-inferior to Novartis's Gleevec brand formulation with respect to clinical efficacy and tolerability.
All-trans retinoic acid (ATRA) plus arsenic trioxide with or without chemotherapy induces high remission rates.
Pediatric patients with acute lymphoblastic lymphoma (ALL) at standard risk for relapse do not benefit from lower-intensity, delayed intensification therapy.
Obinutuzumab-based induction and maintenance chemoimmunotherapy significantly improved progression-free survival.
Serum free light chain measurements correlate more closely with clinical outcomes than urine assessments in patients with light chain multiple myeloma.
Patients with acute myeloid leukemia (AML) who achieve complete remission have improved overall survival.
In higher-risk patients who fail hypomethylating agent treatment, no induction strategy is superior to another with respect to outcomes and safety.
Treatment with brentuximab vedotin is associated with superior clinical outcomes compared with standard of care options.
A higher dose of idarubicin during consolidation therapy improves leukemia-free survival without increasing non-hematologic toxicity.
Consolidation therapy with a condensed schedule of high-dose cytarabine (HDAC) is superior to a standard schedule.
Chemotherapy-free induction with ibrutinib and rituximab is efficacious and well-tolerated among young patients.
Incorporation of bortezomib into VcR-CVAD followed by rituximab maintenance demonstrated high rates of durable remissions.
Venetoclax in combination with low-dose cytarabine appears active in older, treatment-naive patients with acute myeloid leukemia.
Rituximab maintenance following autologous hematopoietic cell transplantation prolongs survival among younger patients with mantle cell lymphoma.
Brentuximab vedotin in combination with RCHP (rituximab, cyclophosphamide, doxorubicin, and prednisone) is active as a frontline therapy.
Ultra-high risk category of patients with diffuse large B-cell lymphoma (DLBCL) who have dismal outcomes on existing therapies.
The combination of nivolumab and ibrutinib is active in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).
Clonal hematopoiesis at the time of primary cancer diagnosis was associated with a significantly increased risk of therapy-related myeloid neoplasm development.
Lenalidomide is a feasible and efficacious option as maintenance therapy for patients with high risk chronic lymphocytic leukemia (CLL).
Anti-CD22 chimeric antigen receptor (CAR) T-cell therapy is safe, feasible, and clinically active in children and young adults.
Despite therapeutic advancements in the treatment of chronic myeloid leukemia (CML), patients who transform to blast phase (CML-BP) have a poor outcome.
Next week, researchers will meet in San Diego, California, at the American Society of Hematology (ASH) 58th Annual Meeting & Exposition.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Changes in Renal Cell Carcinoma Pathologic Staging and Histologic Grading
- Study Identifies Patients With Breast Cancer Who Don't Benefit From Adjuvant Chemo
- CD19 CAR T-Cell Therapies: "Expect an Evolution"
- Hypofractionated WBI Found Noninferior to Conventionally Fractionated WBI
- Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma
- Younger Breast Cancer Patients at Higher Risk for Osteoporosis
- Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified